Integrerad analys av immunrepertoarer i solida tumörer

Tidsperiod: 2020-07-01 till 2022-06-30

Projektledare: Viktor Ljungström

Finansiär: Vetenskapsrådet

Bidragstyp: Bidrag för anställning eller stipendier

Budget: 2 100 000 SEK

Cancer is the second leading cause of death worldwide and even though the last decade has led to several breakthroughs in the molecular characterization of the underlying disease mechanisms there is still an urgent need for biomarkers that allow precise patient stratification. Immune cells interact with the tumor cells and can both promote and impede cancer growth and the repertoire of adaptive immune cells in the tumor is a potential informative biomarker. To gain greater insight into the immune repertoire in solid cancer we plan to investigate 1,200 cases analyzed with whole genome-sequencing and RNA-sequencing to delineate the abundance and diversity of T-cells in the tumor. The results will be integrated with tumor intrinsic aberrations and clinicopathological data, including response to novel immunomodulatory treatment regimens. The results will be validated in a clinical cohort of 30,000 cases collected at Dana Farber Cancer Institute to assess the prognostic and predictive potential of the T-cell repertoire and to evaluate the clinical applicability of the proposed biomarkers. Our findings will lead to further understanding of the role of the adaptive immune system in cancer development, its role in relation to immunomodulatory treatment, and potentially to novel immune-based treatment regimens.